Journal article
A snapshot of smokers after lung and colorectal cancer diagnosis
Cancer, Vol.118(12), pp.3153-3164
06/15/2012
DOI: 10.1002/cncr.26545
PMCID: PMC3342424
PMID: 22271645
Abstract
BACKGROUND: Continued smoking after a cancer diagnosis may adversely affect treatment effectiveness, subsequent cancer risk, and survival. The prevalence of continued smoking after cancer diagnosis is understudied. METHODS: In the multi-regional Cancer Care Outcomes Research and Surveillance cohort (lung cancer [N = 2456], colorectal cancer [N = 3063]), the authors examined smoking rates at diagnosis and 5 months after diagnosis and also study factors associated with continued smoking. RESULTS: Overall, 90.2% of patients with lung cancer and 54.8% of patients with colorectal cancer reported ever smoking. At diagnosis, 38.7% of patients with lung cancer and 13.7% of patients with colorectal cancer were smoking; whereas, 5 months after diagnosis, 14.2% of patients with lung cancer and 9.0% of patients with colorectal cancer were smoking. Factors that were associated independently with continued smoking among patients with nonmetastatic lung cancer were coverage by Medicare, other public/unspecified insurance, not receiving chemotherapy, not undergoing surgery, prior cardiovascular disease, lower body mass index, lower emotional support, and higher daily ever-smoking rates (all P < .05). Factors that were associated independently with continued smoking among patients with nonmetastatic colorectal cancer were male sex, high school education, being uninsured, not undergoing surgery, and higher daily ever-smoking rates (all P < .05). CONCLUSIONS: After diagnosis, a substantial minority of patients with lung and colorectal cancers continued smoking. Patients with lung cancer had higher rates of smoking at diagnosis and after diagnosis; whereas patients with colorectal cancer were less likely to quit smoking after diagnosis. Factors that were associated with continued smoking differed between lung and colorectal cancer patients. Future smoking-cessation efforts should examine differences by cancer type, particularly when comparing cancers for which smoking is a well established risk factor versus cancers for which it is not. Cancer 2012;118: 315364. (C) 2012 American Cancer Society.
Details
- Title: Subtitle
- A snapshot of smokers after lung and colorectal cancer diagnosis
- Creators
- Elyse R. Park - Harvard UniversitySandra J. Japuntich - Harvard UniversityNancy A. Rigotti - Harvard UniversityLara Traeger - Massachusetts General HospitalYulei He - Harvard Medical SchoolRobert B. Wallace - University of IowaJennifer L. Malin - University of California, Los AngelesJennifer P. Zallen - Massachusetts General HospitalNancy L. Keating - Harvard Medical School
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.118(12), pp.3153-3164
- DOI
- 10.1002/cncr.26545
- PMID
- 22271645
- PMCID
- PMC3342424
- NLM abbreviation
- Cancer
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Publisher
- Wiley
- Number of pages
- 12
- Grant note
- MSRG 005-05-CPPB / American Cancer Society Pfizer U01 CA093344; U01 CA093332; U01 CA093324; U01 CA093348; U01 CA093329; U01 CA093339; U01 CA093326; CRS 02-164 / National Cancer Institute (NCI); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Nabi Biopharmaceuticals U01CA093332 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 06/15/2012
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984364445102771
Metrics
27 Record Views